Samuel P. Wertheimer

Since 2017, Dr. Wertheimer has served as Senior Scientific Advisor at Brookline Capital Markets. From 2020 to 2022, he also served as Chairman and Chief Executive Officer of Brookline Capital Acquisition Corp., a special purpose acquisition company (SPAC), before their business combination. From 2012 to 2016, he served as co-founder of Poliwogg, Inc. a financial services firm bringing innovation to healthcare investing. While at Poliwogg, he helped develop the Poliwogg Medical Breakthrough Index that serves as the underlying index for the ALPS Medical Breakthrough ETF (SBIO). From 2000 to 2011, Dr. Wertheimer was a Private Equity Partner at OrbiMed Advisors, LLC, where he was involved in raising and investing four venture capital funds with more than $1.5 billion in committed capital. He previously served on the boards of multiple public and private companies, including Biodel (Nasdaq: BIOD); ChemoCentryx (CCXI); Corus Pharma (acquired by Gilead); InteKrin Therapeutics (acquired by Coherus); NeurAxon; and Salmedix (acquired by Cephalon). He helped bring to market several new drugs including Treanda®, Cayston®, and Orbactiv®. Dr. Wertheimer received his Doctor of Philosophy degree from New York University, his Master of Public Health, with Honors, from Yale University and his Bachelor of Arts from the Johns Hopkins University.